CE / CME
In this module, 5 lung cancer experts review oncology healthcare professional survey results on key educational needs for the multidisciplinary oncology team caring for patients with EGFR-mutated NSCLC, including discussion of standard-of-care practices, the latest clinical data, and ongoing challenges.
Pharmacists: 1.25 contact hours (0.125 CEUs)
Nurses: 1.25 Nursing contact hours
Physicians: Maximum of 1.25 AMA PRA Category 1 Credits™
Released: September 30, 2022
Expiration: September 29, 2023
Share
Edward B Garon, MD, MS
Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Xiuning Le, MD, PhD
Assistant Professor
Division of Cancer Medicine
Department of Throracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Zofia Piotrowska, MD
Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts
Mark A. Socinski, MD
Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania
Helena Yu, MD
Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Provided by Clinical Care Options, LLC
Supported by an educational grant from
Lilly
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with EGFR mutation–positive NSCLC.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Program Director
Edward B Garon, MD, MS
Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Edward B. Garon, MD, MS: consultant/advisor/speaker: ABL Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Dracen, Eisai, EMD Serono, GlaxoSmithKline, Lilly, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio; researcher: ABL Bio, AstraZeneca, Bristol-Myers Squibb, Dynavax Technologies, EMD Serono, Genentech, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis.
Primary Author
Xiuning Le, MD, PhD
Assistant Professor
Division of Cancer Medicine
Department of Throracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Xiuning Le, MD, PhD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Lilly, Novartis, Spectrum; researcher: Boehringer Ingelheim, Regeneron.
Zofia Piotrowska, MD
Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts
Zofia Piotrowska, MD, MHS: researcher (paid to her institution): AbbVie, AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro; consultant/advisor/speaker: AstraZeneca, Blueprint, C4 Therapeutics, Cullinan Oncology, Genentech, Incyte, Janssen, Jazz, Lilly, Medtronic, Takeda.
Mark A. Socinski, MD
Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania
Mark A. Socinski, MD, consultant/advisor/speaker: AstraZeneca, BeiGene, G1 Therapeutics, Genentech, Guardant, Janssen, Jazz, Lilly, Regeneron, Takeda, Sanofi; researcher: AstraZeneca, BeiGene, Cullinan, Daiichi Sankyo, Genentech, Novartis, Spectrum, Takeda.
Helena Yu, MD
Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Helena A. Yu, MD: researcher (paid to her institution): AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Novartis, Pfizer; consultant/advisor/speaker: AstraZeneca, Blueprint Medicine, Daiichi Sankyo, Janssen Oncology.
Staff
Rachael M. Andrie, PhD
Clinical Editor
Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.
Megan Cartwright, PhD
Senior Clinical Editor
Megan Cartwright, PhD, has no relevant financial relationships to disclose.
Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant financial relationships to disclose.
Jason J. Everly, PharmD
Jason Everly has no relevant financial relationships to disclose.
Krista Marcello,
Associate Managing Editor
Krista Marcello has no relevant financial relationships to disclose.
Kevin Obholz, PhD
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC
Jacky Olin, PharmD, has no relevant financial relationships to disclose.
Kristi K. Orbaugh, MSN, RNP, AOCNP
Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana
Kristi Orbaugh has no relevant financial relationships to disclose.
Shara Pantry, PhD
Associate Scientific Director
Shara Pantry, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD
Senior Managing Editor
Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Kristen Rosenthal, PhD
Clinical Editor
Kristen M. Rosenthal, PharmD, has no relevant financial relationships to disclose.
Jill A. Sakai,
Contributing Editor
Jill Sakai, PhD, has no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-231-H01-P.
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 30, 2022, through September 29, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Program Medium
This program has been made available online.
The goal of this activity is to improve the knowledge, competence, and performance of learners to optimally integrate current data needed to make treatment decisions and improve outcomes in the EGFR mutation–positive NSCLC patient population.